GO:0010559 regulation of glycoprotein biosynthetic process: Glycoprotein Synthesis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010559 describes any process that modulates the rate, frequency, or extent of glycoprotein biosynthesis, where glycoproteins are proteins carrying covalently bound monosaccharide residues.
• Glycoprotein biosynthesis regulation operates at multiple levels, including hormonal and nutritional control of glycosyltransferase expression during development.
• Glycoprotein reglucosylation in the endoplasmic reticulum is a key quality-control step that monitors folding and influences biosynthetic flux.
• Altered glycoprotein biosynthesis regulation is linked to diabetes, neurological disorders, and cancer biology through changes in glycan structures and glycoprotein abundance [2,5].
• Population-level glycoform analysis reveals extensive natural variation in glycoprotein biosynthesis, underscoring the need for robust regulatory models.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of regulatory genes within the glycoprotein biosynthetic pathway [1,8].
Description
Glycoproteins are proteins that carry covalently attached carbohydrate chains, and their biosynthesis is a highly regulated process that determines protein stability, trafficking, and function. GO:0010559, regulation of glycoprotein biosynthetic process, encompasses all molecular events that modulate the rate, frequency, or extent of the chemical reactions and pathways leading to glycoprotein formation. This regulatory term is essential for understanding how cells adjust glycosylation in response to developmental cues, metabolic status, and environmental signals [3,7]. Dysregulation of glycoprotein biosynthesis contributes to a wide range of human pathologies, including diabetes, neurological disorders, and cancer [2,5]. For example, zinc-alpha2-glycoprotein expression and function are altered in metabolic and neurological conditions, highlighting the importance of regulatory control. Similarly, population-level analysis of glycoprotein glycoforms has revealed extensive inter-individual variation that may influence disease susceptibility and therapeutic responses. Researchers studying GO:0010559 aim to identify the genes, enzymes, and signaling pathways that control glycoprotein production. Key regulatory nodes include hormonal and nutritional factors that modulate glycosyltransferase activity during postnatal development, as well as endoplasmic reticulum-based reglucosylation cycles that ensure proper folding and biosynthetic efficiency. Understanding these mechanisms provides a foundation for developing targeted interventions in diseases where glycoprotein homeostasis is disrupted [1,8].
regulation of glycoprotein biosynthetic process At A Glance
| GO ID | GO:0010559 |
|---|---|
| GO term | regulation of glycoprotein biosynthetic process |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the rate, frequency, or extent of glycoprotein biosynthesis |
| Definition source | QuickGO definition based on published literature |
| Related processes | Glycosylation, protein folding, endoplasmic reticulum quality control |
| Key regulatory factors | Hormonal and nutritional signals, glycosyltransferases, reglucosylation enzymes |
| Disease relevance | Diabetes, neurological disorders, cancer, metabolic syndromes |
What Is GO:0010559?
GO:0010559, regulation of glycoprotein biosynthetic process, is defined as any process that modulates the rate, frequency, or extent of the chemical reactions and pathways resulting in the formation of a glycoprotein, a protein that contains covalently bound glycose residues, most commonly as oligosaccharide or fairly small polysaccharide but occasionally as monosaccharide.
Why Is regulation of glycoprotein biosynthetic process Important in Cell Biology?
Regulation of glycoprotein biosynthetic process is critical because glycoproteins participate in nearly every aspect of cellular and organismal physiology, including cell adhesion, signaling, immune recognition, and extracellular matrix formation [3,7]. The precise control of glycoprotein biosynthesis ensures that proteins acquire the correct glycan structures needed for their function, and disruptions in this regulation can lead to disease [2,5]. For instance, altered glycosylation of beta1-integrin affects receptor clustering and lateral mobility, which can influence cell migration and cancer progression. Moreover, population-level glycoform analysis has demonstrated that natural variation in glycoprotein biosynthesis may affect drug efficacy and safety. Therefore, understanding GO:0010559 is essential for basic biology and translational research.
• Glycoprotein biosynthesis regulation controls protein folding and quality control in the endoplasmic reticulum.
• Hormonal and nutritional factors regulate intestinal glycoprotein glycosylation during postnatal development.
• Zinc-alpha2-glycoprotein expression and function are linked to metabolic and neurological disorders.
• Altered glycoprotein biosynthesis contributes to diabetes complications and driving-related risks.
• Population-level glycoform variation impacts therapeutic monoclonal antibody efficacy.
• Galectin-3 modulates beta1-integrin clustering, affecting cell adhesion and signaling.
• Mechanosensing at the vascular interface involves glycoprotein-mediated processes.
• Dysregulated glycoprotein biosynthesis is a hallmark of cancer and metastasis.
• Glycoprotein reglucosylation is essential for ER-associated degradation and protein quality control.
• Understanding regulatory mechanisms aids in designing glycoprotein-based therapeutics.
What Happens During regulation of glycoprotein biosynthetic process?
Transcriptional and hormonal control of glycosyltransferases
In simple terms: Cells adjust the enzymes that build glycans in response to hormones and nutrients.
The regulation of glycoprotein biosynthesis begins with the controlled expression of glycosyltransferases and related enzymes. During postnatal development, hormonal and nutritional factors modulate the glycosylation of intestinal glycoproteins, thereby influencing gut maturation and function. This level of regulation ensures that glycoprotein production matches the physiological needs of the organism.
Endoplasmic reticulum reglucosylation cycle
In simple terms: In the ER, a cycle of adding and removing glucose helps proteins fold correctly.
Glycoprotein reglucosylation in the endoplasmic reticulum is a key regulatory step that monitors protein folding and determines whether a glycoprotein proceeds through the secretory pathway or is targeted for degradation. This cycle involves the sequential action of glucosidases and glucosyltransferases, and its modulation directly affects the rate of glycoprotein biosynthesis.
Glycan processing and quality control
In simple terms: After initial attachment, glycans are trimmed and modified to create mature glycoproteins.
Following reglucosylation, glycoproteins undergo further glycan processing in the Golgi apparatus, where additional sugars are added or removed. This processing is regulated by the availability of nucleotide sugars and the activity of specific glycosyltransferases, which together determine the final glycoform. The regulation of these steps ensures that glycoproteins acquire the appropriate structures for their functions.
Integration with cellular signaling and mechanosensing
In simple terms: Glycoprotein biosynthesis is tuned by signals from the cell's environment, including mechanical forces.
Regulation of glycoprotein biosynthesis is integrated with cellular signaling pathways. For example, mechanosensing at the vascular interface involves glycoprotein-mediated events that influence endothelial cell behavior. Additionally, galectin-3 alters the lateral mobility and clustering of beta1-integrin receptors, demonstrating how glycan-binding proteins can modulate glycoprotein function and downstream signaling.
Key Genes Involved in GO:0010559 regulation of glycoprotein biosynthetic process
The following genes and proteins are key players in the regulation of glycoprotein biosynthetic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GAL3 | Galectin-3, a glycan-binding protein that modulates beta1-integrin clustering | Studied for its role in cell adhesion and cancer |
| AZGP1 | Zinc-alpha2-glycoprotein, involved in metabolic and neurological functions | Linked to diabetes and neurological disorders |
| UGT | UDP-glucuronosyltransferases, enzymes that add glucuronic acid to glycoproteins | Regulated by hormonal and nutritional factors |
| UGGT | UDP-glucose:glycoprotein glucosyltransferase, central to reglucosylation | Key regulator of ER quality control |
| GANAB | Glucosidase II alpha subunit, removes glucose from glycoproteins | Participates in reglucosylation cycle |
| PRKAA1 | AMP-activated protein kinase, senses energy status | May influence glycoprotein biosynthesis via metabolic signaling |
| INS | Insulin, hormone regulating glucose metabolism | Affects glycoprotein biosynthesis in diabetes |
| IGF1 | Insulin-like growth factor 1 | Modulates glycosylation during development |
| EGFR | Epidermal growth factor receptor, a glycoprotein | Its glycosylation affects signaling |
| ITGB1 | Integrin beta-1, a glycoprotein involved in cell adhesion | Regulated by galectin-3 |
| CD44 | Cell surface glycoprotein involved in cell migration | Glycosylation changes affect cancer progression |
| MUC1 | Mucin 1, a heavily glycosylated protein | Altered glycosylation in cancer |
| B4GALT1 | Beta-1,4-galactosyltransferase 1 | Adds galactose to glycans |
| ST6GAL1 | Alpha-2,6-sialyltransferase 1 | Sialylates glycoproteins, affecting function |
| FUT8 | Fucosyltransferase 8 | Adds fucose to glycoproteins |
| MAN2A1 | Mannosidase alpha class 2A member 1 | Processes glycans in Golgi |
| HSPA5 | BiP, ER chaperone involved in glycoprotein folding | Regulates glycoprotein biosynthesis |
How Is regulation of glycoprotein biosynthetic process Regulated?
The regulation of glycoprotein biosynthetic process is itself controlled by multiple signaling pathways and environmental cues. Hormonal and nutritional factors, such as insulin and IGF-1, modulate glycosyltransferase expression and activity during development. In the endoplasmic reticulum, the reglucosylation cycle is regulated by the availability of UDP-glucose and the activity of UGGT and glucosidase II. Additionally, metabolic sensors like AMPK may integrate energy status with glycoprotein production. At the cell surface, galectin-3 can influence glycoprotein function by altering receptor clustering. These layers of regulation ensure that glycoprotein biosynthesis is responsive to physiological demands.
regulation of glycoprotein biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AZGP1 | Diabetes, neurological disorders | Knockout mouse or cell line to study metabolic and neuronal phenotypes |
| GAL3 | Cancer, cell adhesion | Overexpression or knockout in cancer cell lines to assess migration |
| UGGT | ER storage diseases, protein folding disorders | Point mutation knock-in to mimic patient mutations |
| ITGB1 | Cancer, mechanosensing | Knock-in of glycosylation-deficient mutants [1,8] |
| ST6GAL1 | Cancer, immune disorders | Overexpression in cell models to study sialylation effects |
Diabetes and metabolic disorders
Dysregulation of glycoprotein biosynthesis is implicated in diabetes and its complications. Zinc-alpha2-glycoprotein expression is altered in metabolic conditions, and its function may contribute to insulin resistance. Furthermore, diabetes affects driving performance, highlighting the systemic impact of metabolic dysregulation. Understanding how glycoprotein biosynthesis is regulated in diabetes could lead to new therapeutic strategies.
Neurological disorders
Zinc-alpha2-glycoprotein has been studied in the context of neurological disorders, where changes in its expression or glycosylation may affect neuronal function. Proper regulation of glycoprotein biosynthesis is essential for maintaining synaptic plasticity and neuronal survival, and its disruption may contribute to neurodegeneration.
Cancer and metastasis
Altered glycoprotein biosynthesis is a hallmark of cancer. Galectin-3 modulates beta1-integrin clustering, which can promote cell migration and invasion. Additionally, population-level glycoform analysis has revealed cancer-associated changes in glycoprotein structures. Targeting the regulatory mechanisms of glycoprotein biosynthesis may offer new avenues for cancer therapy.
From regulation of glycoprotein biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of a glycosyltransferase alter glycoprotein biosynthesis? | CRISPR knockout cell line or mouse model |
| How does a point mutation in UGGT affect reglucosylation? | Point mutation knock-in via CRISPR |
| Can a tagged glycosyltransferase reveal its localization? | Knock-in of fluorescent or epitope tag |
| What is the effect of overexpressing galectin-3 on integrin clustering? | Overexpression cell model |
| Does nutritional status regulate intestinal glycoprotein glycosylation? | In vivo dietary manipulation in animal models |
| How do disease-associated mutations in AZGP1 affect its function? | Knock-in of patient mutations in cell lines |
How to Study the regulation of glycoprotein biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Glycan composition and structure | Profiling glycoforms in disease vs. normal |
| CRISPR screen | Genes affecting glycoprotein biosynthesis | Identifying novel regulators |
| Western blot | Protein abundance and glycosylation state | Validating knockout or overexpression effects |
| Flow cytometry | Cell surface glycoprotein levels | Assessing glycosylation changes |
| Immunofluorescence | Subcellular localization of glycoproteins | Studying ER/Golgi trafficking |
| Lectin microarray | Glycan binding patterns | Comparing glycosylation profiles |
| qRT-PCR | mRNA levels of glycosyltransferases | Measuring transcriptional regulation |
| Co-immunoprecipitation | Protein-protein interactions | Identifying regulatory complexes |
Glycomics and mass spectrometry
Mass spectrometry-based glycomics allows comprehensive profiling of glycoprotein glycoforms, revealing changes in glycosylation patterns under different regulatory conditions. This method is essential for quantifying the effects of genetic or environmental perturbations on glycoprotein biosynthesis.
CRISPR screening
Genome-wide CRISPR screens can identify genes that regulate glycoprotein biosynthesis. By coupling glycosylation-specific reporters with knockout libraries, researchers can uncover novel regulatory factors [1,8].
Proteomics and Western blotting
Proteomic approaches and Western blotting are used to measure the abundance and glycosylation status of specific glycoproteins, such as beta1-integrin or zinc-alpha2-glycoprotein, following regulatory perturbations [1,2].
Imaging and flow cytometry
Fluorescence microscopy and flow cytometry with glycan-binding lectins or antibodies can visualize glycoprotein distribution and clustering at the cell surface, providing insights into regulatory mechanisms [1,8].
How CRISPR Can Be Used to Study GO:0010559 regulation of glycoprotein biosynthetic process
Knockout
CRISPR knockout of glycosyltransferase genes or regulatory factors can abolish specific glycosylation steps, allowing researchers to determine their necessity in glycoprotein biosynthesis. For example, knocking out UGGT would disrupt the reglucosylation cycle and impair glycoprotein folding.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to dissect catalytic residues. For instance, mutating the catalytic domain of a glycosyltransferase can reveal its role in substrate specificity and regulation.
Knock-in
Knock-in of tagged versions of glycosyltransferases or glycan-binding proteins enables live-cell imaging and proteomic analysis, providing insights into their dynamic regulation. Knock-in of patient mutations can model disease mechanisms.
Overexpression
Overexpression of regulatory genes, such as galectin-3, can enhance or disrupt glycoprotein biosynthesis, leading to altered cell behavior. This approach is useful for gain-of-function studies.
How EDITGENE Supports regulation of glycoprotein biosynthetic process Research
Researchers studying regulation of glycoprotein biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in glycosylation changes or is merely a bystander. EDITGENE provides comprehensive CRISPR-based services to enable such causal investigations.
Contact EDITGENE today to design your custom CRISPR model for regulation of glycoprotein biosynthetic process research.
Frequently Asked Questions About regulation of glycoprotein biosynthetic process
What is GO:0010559?
GO:0010559 is the Gene Ontology term for regulation of glycoprotein biosynthetic process, which encompasses any process that modulates the rate, frequency, or extent of glycoprotein formation.
What genes are involved in regulation of glycoprotein biosynthetic process?
Key genes include GAL3, AZGP1, UGGT, GANAB, and various glycosyltransferases such as B4GALT1 and ST6GAL1 [1,2,3,7].
How is glycoprotein biosynthesis regulated?
It is regulated at multiple levels, including hormonal and nutritional control of glycosyltransferase expression, ER reglucosylation cycles, and glycan processing in the Golgi [3,7].
What diseases are associated with dysregulated glycoprotein biosynthesis?
Diseases include diabetes, neurological disorders, and cancer, where altered glycosylation affects protein function and cell behavior [1,2,5].
What methods are used to study regulation of glycoprotein biosynthetic process?
Methods include mass spectrometry, CRISPR screens, Western blotting, flow cytometry, and lectin microarrays [1,6].
How can CRISPR be used to study glycoprotein biosynthesis?
CRISPR enables knockout, point mutation, knock-in, and overexpression of regulatory genes to test their causal roles in glycosylation [1,3,7].
What is the role of UGGT in glycoprotein biosynthesis?
UGGT catalyzes the reglucosylation of glycoproteins in the ER, a key step in quality control and regulation of biosynthesis.
How does galectin-3 affect glycoprotein function?
Galectin-3 alters the lateral mobility and clustering of beta1-integrin receptors, thereby modulating cell adhesion and signaling.
What is zinc-alpha2-glycoprotein and how is it regulated?
Zinc-alpha2-glycoprotein is a secreted glycoprotein whose expression and function are linked to metabolic and neurological disorders; its biosynthesis is subject to hormonal and nutritional regulation.
Why is population-level glycoform analysis important?
It reveals natural variation in glycoprotein biosynthesis that can impact drug efficacy and disease susceptibility.
Conclusion
Regulation of glycoprotein biosynthetic process (GO:0010559) is a fundamental biological process that ensures proper protein glycosylation, folding, and function. Its dysregulation contributes to major human diseases, including diabetes, neurological disorders, and cancer [1,2,5]. Advances in CRISPR-based models and glycomic technologies are enabling researchers to dissect the regulatory networks with unprecedented precision [3,6,7]. EDITGENE offers a comprehensive suite of services to support these investigations, from knockout and knock-in models to CRISPR screening and bioinformatics.
References
- 1. Yang EH et al.. 2017. Galectin-3 alters the lateral mobility and clustering of β1-integrin receptors.. PLoS One 12(10):e0184378 PMID: 29016609
- 2. Wei X et al.. 2019. Expression and Function of Zinc-α2-Glycoprotein.. Neurosci Bull 35(3):540-550 PMID: 30610461
- 3. Biol-N'garagba MC et al.. 2003. Regulation of the intestinal glycoprotein glycosylation during postnatal development: role of hormonal and nutritional factors.. Biochimie 85(3-4):331-52 PMID: 12770772
- 5. Inkster B et al.. 2013. Diabetes and driving.. Diabetes Obes Metab 15(9):775-83 PMID: 23350766
- 6. Toledo AG et al.. 2026. Population-level analysis of glycoprotein glycoforms.. MAbs 18(1):2665879 PMID: 42059453
- 7. Trombetta ES et al.. 2005. Glycoprotein reglucosylation.. Methods 35(4):328-37 PMID: 15804604
- 8. Tarbell JM et al.. 2014. Mechanosensing at the vascular interface.. Annu Rev Biomed Eng 16:505-32 PMID: 24905872
